Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Twenty years of adverse drug reactions: a look back – part 2

Twenty years of adverse drug reactions: a look back – part 2 SummaryAfter 20 years, Robin Ferner and Christopher Anton, who took on responsibility for the Adverse Drug Reaction Bulletin from its founder Professor Dai Davies, are handing over responsibility to Professor Kim Dalhoff and his colleague Dr Jon Andersen in Copenhagen. They take the opportunity to review some interesting, important, or unusual clinical aspects of adverse drug reactions encountered over the last twenty years. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Adverse Drug Reaction Bulletin Wolters Kluwer Health

Twenty years of adverse drug reactions: a look back – part 2

Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/twenty-years-of-adverse-drug-reactions-a-look-back-part-2-2YT20I2Wy4

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0044-6394
eISSN
2159-7774
DOI
10.1097/FAD.0000000000000034
Publisher site
See Article on Publisher Site

Abstract

SummaryAfter 20 years, Robin Ferner and Christopher Anton, who took on responsibility for the Adverse Drug Reaction Bulletin from its founder Professor Dai Davies, are handing over responsibility to Professor Kim Dalhoff and his colleague Dr Jon Andersen in Copenhagen. They take the opportunity to review some interesting, important, or unusual clinical aspects of adverse drug reactions encountered over the last twenty years.

Journal

Adverse Drug Reaction Bulletin – Wolters Kluwer Health

Published: Jun 1, 2018

References

  • Drug-induced hyperglycaemia and diabetes
  • Consensus development conference on antipsychotic drugs and obesity and diabetes
  • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
  • Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
  • Almost all antipsychotics result in weight gain: a meta-analysis
  • Treatment with antipsychotics and the risk of diabetes in clinical practice
  • sglt2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis
  • Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: a case report
  • Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
  • Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
  • Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
  • Drug-induced hypokalaemia
  • Drug-induced hypomagnesaemia
  • Drug-induced metabolic acidosis
  • Sitagliptin-associated angioedema
  • Angiotensin-converting enzyme inhibitor-induced small-bowel angioedema: clinical and imaging findings in 20 patients
  • Penile angioedema developing after 3 years of ACEI therapy
  • Angioedema: a review of 367 episodes presenting to three tertiary care hospitals
  • Drug safety in Aboriginal Australians: three cases of angiotensin-converting enzyme inhibitor angioedema
  • Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
  • Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors
  • Orolingual angioedema during or after thrombolysis for cerebral ischemia
  • Double trouble: tPA-induced angioedema
  • Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema
  • Sitagliptin and Angioedema
  • Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema
  • Anaphylaxis to walnuts and pine nuts induced by ACE
  • Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans
  • Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors
  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
  • Molecular and biochemical aspects of the PD-1 checkpoint pathway
  • Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
  • Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
  • fulminant myocarditis with combination immune checkpoint blockade
  • Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
  • Transient eosinophilic pneumonia secondary to use of a vaginal cream
  • Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?
  • Montelukast and Churg-Strauss syndrome
  • Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment
  • Drug-induced pleural disease
  • Drug-induced mitochondrial dysfunction and cardiotoxicity
  • New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics
  • Cardiomyopathy associated with targeted therapy for breast cancer
  • Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer
  • Exposure to amphetamines leads to development of amphetamine type stimulants associated cardiomyopathy (ATSAC)
  • The cardiac complications of methamphetamines
  • Myocarditis by mesalazine with cardiac magnetic resonance imaging
  • Eosinophilic myocarditis during treatment with olanzapine – report of two possible cases
  • Fever, eosinophilia, and death: a case of minocycline hypersensitivity
  • Myocarditis associated with infliximab: a case report and review of the literature
  • Myo-pericarditis secondary to ledipavir-sofosbuvir therapy
  • Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
  • Adverse cardiac effects associated with clozapine
  • Clozapine induced myocarditis: a rare but fatal complication
  • Myocarditis during clozapine treatment
  • Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology
  • Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003
  • Clozapine-induced myocarditis
  • Clozapine rechallenge after myocarditis
  • Successful clozapine re-challenge following myocarditis
  • Adverse cardiac effects associated with clozapine
  • Aprotinin: suspension of marketing authorisations
  • The risk associated with aprotinin in cardiac surgery
  • A comparison of aprotinin and lysine analogues in high-risk cardiac surgery
  • Aprotinin and cardiac surgery: a sorry tale of evidence misused
  • Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin